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Background In-transit metastases (ITMs) in melanoma are associated with poor prognosis, 
however a significant proportion of these patients survive for extended periods without further 
disease progression. We routinely use locoregional treatment e.g. Diphencyprone (DPCP) 
and/or isolated limb infusion (ILI) as long-term palliation. This study aimed to identify correct 
sequencing of these therapies based on disease burden and progression. 
Method Retrospective evaluation of all melanoma patients with ITMs treated with 
DPCP/ILI/both from 2010-2017 at our Cancer Centre was performed. Patients were initially 
assessed in a multidisciplinary setting and empirically prescribed DPCP for low-disease 
burden, ILI for high-disease burden. Patient demographics, tumour characteristics, response to 
therapy, ITM progression and patient outcomes were analysed.  




Results 78 patients (M:F=30:48), aged 47-95years (median 74years) treated with 
DPCP/ILI/both (n=44/21/13) were identified. Progression-free survival (PFS) was significantly 
increased in patients responsive to DPCP or ILI as initial treatment. Patients who failed on 
DPCP and subsequently treated with ILI had a significantly increased PFS compared to DPCP 
alone (p=0.026,HR=0.048). This was not the case with patients who were treated with DPCP 
following failed ILI. All patients who failed to respond to the initial therapy progressed within 
6 months.  
Conclusion Our study shows that careful stratification ITM patients according to disease 
burden is fundamental to optimal outcomes. High-disease burden patients benefit from initial 
ILI; low-disease burden patients should commence on DPCP. ILI can be considered in DPCP 
patients who fail early. Systemic therapy should be considered when locoregional therapies fail 




According to the 8
th
 edition of the AJCC Melanoma Staging System, in-transit disease is 
defined as regional spread of tumour via lymphatic vessels in the dermis or subcutaneous tissue 
outside of nodal basins; in-transit metastases (ITMs) are included in stages IIIC and IIID and 
are considered locally advanced disease, associated with a 69% and 32% melanoma-specific 
survival rate respectively
1
. ITMs occur in up to 12% of all melanoma patients
2-5
. Within this 
cohort the disease volume, burden and progression can be diverse and variable.  Currently there 
is no consensus on the optimal treatment protocol for ITMs. Multiple therapeutic modalities 
exist for the management of ITMs with the aim of producing locoregional control (palliation) 
of the disease. In our quaternary referral cancer centre we routinely use topical diphencyprone 
(DPCP) and isolated limb infusion (ILI)  as our two locoregional treatment options for ITMs as 
alternatives to systemic therapy in carefully selected patients.  
 




The exact mechanisms of actions of DPCP, a topical immunotherapy agent, in melanoma is 
unknown; it is a potent contact sensitizer that induces contact hypersensitivity reactions. The 
induced cytokines are IL-24 and IL-9, which are known to suppress melanoma activity
7
. We 
have previously described our experience with DPCP for the management of low-disease 
burden ITMs
7
, where a response rate of  84% was demonstrated. There are several advantages 
to DPCP, including the ability for the patient to self-administer the treatment over large areas 
of the affected skin and it is relatively well-tolerated
8
. ILI is a minimally invasive, closed 
circuit technique that delivers concentrated doses of cytotoxic drugs (mephalan usually 
combined with actinomycin D) to the affected limb to achieve disease control
9,10
. Whilst, good 
locoregional control rates (overall response rate of 60-80%) have been described by multiple 
centres
11-13
, the palliation comes at a cost of significant limb toxicity for some, which can 
significantly prolong the patient’s rehabilitation. 
  
With multiple modalities for treatment of ITMs; stratifying the appropriate treatment option is 
a challenge to the modern specialist skin multidisciplinary team (SSMDT).  The complexity of 
this stratification is increased when the disease fails to respond to, becomes resistant to, or 
progresses on a given treatment. It is clear from multiple studies of both ILI and DPCP
13,14
 that 
locoregional disease progression is associated with a poor prognosis in terms of overall 
survival. However, it is most commonly observed
14
 that the patients’ first site of relapse is 
locoregionally with no evidence of distant disease. Given the separate mechanism of action, it 
is unclear whether further locoregional treatments should be employed rather than proceeding 
to systemic therapy, particularly if the overall disease burden remains low.  Accordingly, the 
aim of this study was to identify the correct sequencing of these therapies based on disease 
burden and progression.  
 
Methods 




A retrospective evaluation of all melanoma patients with ITMs treated with DPCP, ILI or both 
from 2010 to 2017 at the Norfolk & Norwich Skin Tumour Unit, a tertiary/quaternary 
melanoma service was performed. Within the context of a SSMDT, this cohort of patients were 
initially assessed and empirically prescribed DPCP for low disease burden and ILI for high 
disease burden as directed by the senior clinicians after clinical review in the multidisciplinary 
tertiary referral clinic (senior authors MM, JG). The treatment protocol for DPCP has been 
described by the senior authors
7
. Our protocol for performing ILI is nationally standardised and 
is very similar to that described by Professor Thompson’s team at MIA
10,13
. Patients were 
followed up at 6-12 week intervals following the initiation of treatment by the clinician in the 
MDT clinic, where the patients’ response to treatment was observed and recorded. In patients 
who failed their initial treatment and prior to consideration for commencing systemic therapy, 
the counterpart therapy was considered, i.e. patients who fail to respond to DPCP were 
considered for ILI and those who failed on ILI were treated with DPCP. 
 
For the purposes of analysis, data regarding patient demographics, histopathological features of 
the primary melanoma, sequence of and response to therapy or therapies, ITM progression and 
patient outcomes were collected from a prospective institutional melanoma database. Kaplan-
Meier probability estimate curves were generated to assess melanoma-specific (MSS) and 
progression-free survival (PFS). 
 
Results 
78 melanoma patients with ITMs treated with DPCP, ILI or both (n=44, 21, 13 respectively) 
were identified. 1 patient in the ILI-only cohort and 2 patients in the DPCP + ILI therapy 
cohort underwent ILI twice. Male to female ratio was 30:48; age ranged from 47 to 95 years 
(median 74 years). Primary melanoma distribution was limited to the limbs for ILI treatment as 
predicted; however, DPCP therapy was offered to patients who had head and neck or truncal 
melanomas and associated ITMs (Table 1).  





Median PFS in the ILI-only group was 18 months, compared to 6 months in the DPCP-only 
group (p=0.22, not significant (NS)). Melanoma specific survival (MSS) was significantly 
increased in patients who demonstrated a response to either DPCP or ILI as the initial treatment 
compared to the dual therapy cohort, where median MSS was 32 months on DPCP, 69 months 
on ILI and 39 months on dual therapy respectively (p=0.01, Figure 1).  
 
Patients who failed to respond to DPCP and were subsequently treated with ILI had a 
significantly increased PFS compared to DPCP alone (DPCP-only 8 months vs DPCP+ILI 20 
months) (p=0.026, HR=0.47, Figure 2). This was not the case with patients who were treated 
with DPCP following failed ILI where PFS was 69 months in the ILI-only group compared to 
38.5 months in the ILI+DPCP group (p=0.36, NS). 
  
In all categories, we noted that patients who failed to respond to the initial therapy progressed 
within 6 months. 
 
Discussion 
Treatment for ITMs is not standardized i.e. there is no set sequencing of therapy or treatment 
strategy for this cohort of patients. NICE guidance for treating ITMs is palliative surgery in the 
first instance; however, in patients where surgery is not appropriate, a selection of treatment 
options ranging from systemic therapy, regional chemotherapy and local agents are 
recommended
15
. The aim of these is to gain locoregional control of the disease to allow long-
term palliation of these patients. However, there is currently very little data available in 
comparing outcomes between non-surgical interventions. 
 
In an MIA study, median survival following complete response from ILI for treatment of ITMs 
was 53 months
10
, similar to our data where MSS was 69 months. Similarly, Read et al. 




demonstrated that median overall survival from DPCP treatment commencement was 20.9 
months and a disease-free survival of 12.3 months, comparable to our data
14
. 
ILI following failed DPCP improves MSS. Our data is seeming to suggest that ILI not only has 
a direct effect on ITMs as regional chemotherapy but is partly immune mediated. 
Disease burden for ITMs was not definitively described in our study. PET-CTs and medical 
photography were used within a multidisciplinary setting to determine whether a patient was 
deemed to have low- or high-disease burden of ITMs; this, in turn, outlined their initial 
treatment strategy. Defining standardized ITM disease burden categories will further improve 
selecting appropriate management for this cohort of patients.  
 
Our study shows that careful stratification ITM patients according to disease burden is 
fundamental to optimal patient outcomes. Those with high-disease burden benefit from initial 
ILI, whereas those with low-disease burden can be trialled with DPCP. ILI can be considered 
in DPCP patients who fail early. Systemic therapy should be considered when locoregional 
therapies fail after 6 months or after rapid relapse following ILI. We suggest that treatment 
priority should be based on volume and site of disease. We propose the following algorithm 
(Figure 3) on managing patients with ITMs.  
 
Conclusion 
Our data suggests that DPCP and ILI both have roles in managing ITMs by offering prolonged 
locoregional disease control, and reserving systemic therapies for disease progression. 
However, disease burden is an important consideration when basing initial treatment strategies. 
Comparatives studies is merited to more precisely evaluate individual non-surgical treatment 
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Figure 1: Melanoma-specific survival comparing patients undergoing ILI-only, DPCP-only and dual 







Figure 2. PFS in patients who respond to first line DPCP vs first line ILI and those who were treated 
with dual therapy (DPCP first). 
 






Figure 3. Proposed sequencing algorithm on managing patients with in-transit metastasis using 
Diphencyprone, isolated limb infusion and systemic therapy. 
 
Table 1: patient demographics and primary melanoma characteristics (N/A: not applicable) 
 
 DPCP only ILI only DPCP and ILI 
Number of patients (n) 44 21 13 
Median age (years) 77 70 75 
Primary melanoma distribution 
Head and neck 8 N/A N/A 
Trunk 7 N/A N/A 
Upper limb 5 1 0 
Lower limb 24 18 13 
Unknown primary 0 2 0 
Median Breslow thickness 2.5 2.65 2.5 






Yes 19 6 6 
No 23 8 2 




         
